February 2016

Apellis Completes $47 Million Series D Financing

Louisville, Ky., Feb. 12, 2016 –¬†Apellis Pharmaceuticals, Inc., today announced that it has completed a $47.1 million Series D preferred stock financing, co-led by new investors Cormorant Asset Management, Hillhouse Capital Group and venBio Global Strategic Fund, joining existing investors Morningside Venture Investments, AJU IB…